CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10100|
|Strength||100 mg and 400 mg vials|
|Indication||Malignant Pleural Mesothelioma|
|Funding Request||In combination with pemetrexed and cisplatin or carboplatin (for cisplatin ineligible patients), for first-line treatment in patients with unresectable malignant pleural mesothelioma|
|Pre Noc Submission||Yes|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Hoffmann-La Roche Limited|
|Clarification||Hoffmann-La Roche Limited requested a voluntary withdrawal of the pCODR 10100 Bevacizumab (Avastin) MPM Submission. As per pCODR Procedures B220.127.116.11 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.|
|Submission Date||December 16, 2016|
|Submission Deemed Complete||December 23, 2016|
|Submission Type||New Indication|
|Prioritization Requested||Requested and Not Granted|
|Stakeholder Input Deadline ‡||January 9, 2017|
|Check-point meeting||February 27, 2017|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.